MorphoSys Is At BIO Looking To Buy
Flush German biotech looks to in-license or acquire clinical stage biologics to even out its pipeline as it edges from fee-for-service to development business model.
Flush German biotech looks to in-license or acquire clinical stage biologics to even out its pipeline as it edges from fee-for-service to development business model.